|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members.
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen International expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gluck S, de Snoo F, Peeters J,
Stork-Sloots L and Somlo G: Molecular subtyping of early-stage
breast cancer identifies a group of patients who do not benefit
from neoadjuvant chemotherapy. Breast Cancer Res Treat.
139:759–767. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel
Members. Tailoring therapies-improving the management of early
breast cancer: St Gallen International expert consensus on the
primary therapy of early breast cancer 2015. Ann Oncol.
26:1533–1546. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tian S, Roepman P, Van't Veer LJ, Bernards
R, de Snoo F and Glas AM: Biological functions of the genes in the
mammaprint breast cancer profile reflect the hallmarks of cancer.
Biomark Insights. 5:129–138. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009.
2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Müller BM, Keil E, Lehmann A, Winzer KJ,
Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S,
Schoenegg W, et al: The endopredict gene-expression assay in
clinical practice-performance and impact on clinical decisions.
PLoS One. 8(e68252)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Filipits M, Rudas M, Jakesz R, Dubsky P,
Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, et al:
A new molecular predictor of distant recurrence in ER-positive,
HER2-negative breast cancer adds independent information to
conventional clinical risk factors. Clin Cancer Res. 17:6012–6020.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Duffy MJ, Harbeck N, Nap M, Molina R,
Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in
breast cancer: Updated guidelines from the European Group on Tumor
Markers (EGTM). Eur J Cancer. 75:284–298. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Weigelt B, Reis-Filho JS and Swanton C:
Genomic analyses to select patients for adjuvant chemotherapy:
Trials and tribulations. Ann Oncol. 23 (Suppl 10):x211–x218.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van Steenhoven JEC, Kuijer A, van Diest
PJ, van Gorp JM, Straver M, Elias SG, Wesseling J, Rutgers E,
Timmer-Bonte JNH, Nieboer P, et al: Conventional pathology versus
gene signatures for assessing Luminal A and B type breast cancers:
Results of a prospective cohort study. Genes (Basel).
9(261)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bustreo S, Osella-Abate S, Cassoni P,
Donadio M, Airoldi M, Pedani F, Papotti M, Sapino A and Castellano
I: Optimal Ki67 cut-off for luminal breast cancer prognostic
evaluation: A large case series study with a long-term follow-up.
Breast Cancer Res Treat. 157:363–371. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dubsky P, Filipits M, Jakesz R, Rudas M,
Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, et al:
EndoPredict improves the prognostic classification derived from
common clinical guidelines in ER-positive, HER2-negative early
breast cancer. Ann Oncol. 24:640–647. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cuzick J, Dowsett M, Pineda S, Wale C,
Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al:
Prognostic value of a combined estrogen receptor, progesterone
receptor, Ki-67, and human epidermal growth factor receptor 2
immunohistochemical score and comparison with the Genomic Health
recurrence score in early breast cancer. J Clin Oncol.
29:4273–4278. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: A meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Focke CM, van Diest PJ and Decker T: St
Gallen 2015 subtyping of luminal breast cancers: Impact of
different Ki67-based proliferation assessment methods. Breast
Cancer Res Treat. 159:257–263. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members. Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen International expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Villarreal-Garza C, Lopez-Martinez EA,
Deneken-Hernandez Z, Maffuz-Aziz A, Muñoz-Lozano JF,
Barragan-Carrillo R, Ramos-Elias P, Moreno B, Diaz-Perez H,
Peña-Curiel O, et al: Change in therapeutic management after the
EndoPredict assay in a prospective decision impact study of Mexican
premenopausal breast cancer patients. PLoS One.
15(e0228884)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cardoso F, van't Veer LJ, Bogaerts J,
Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S,
DeLorenzi M, et al: 70-Gene signature as an aid to treatment
decisions in early-stage breast cancer. N Engl J Med. 375:717–729.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Allison KH, Hammond ME, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Penault-Llorca F and Radosevic-Robin N:
Ki67 assessment in breast cancer: An update. Pathology. 49:166–171.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
International Ki67 in breast cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Viale G, de Snoo FA, Slaets L, Bogaerts J,
van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas
A, Russo L, et al: Immunohistochemical versus molecular (BluePrint
and MammaPrint) subtyping of breast carcinoma. Outcome results from
the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res Treat.
167:123–131. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826.
2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sahebjam S, Aloyz R, Pilavdzic D, Brisson
ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr and Panasci LC:
Ki 67 is a major, but not the sole determinant of Oncotype Dx
recurrence score. Br J Cancer. 105:1342–1345. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ahmed W, Malik MFA, Saeed M and Haq F:
Copy number profiling of Oncotype DX genes reveals association with
survival of breast cancer patients. Mol Biol Rep. 45:2185–2192.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bertucci F, Finetti P, Viens P and
Birnbaum D: EndoPredict predicts for the response to neoadjuvant
chemotherapy in ER-positive, HER2-negative breast cancer. Cancer
Lett. 355:70–75. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Maranta AF, Broder S, Fritzsche C, Knauer
M, Thürlimann B, Jochum W and Ruhstaller T: Do YOU know the Ki-67
index of your breast cancer patients? Knowledge of your
institution's Ki-67 index distribution and its robustness is
essential for decision-making in early breast cancer. Breast.
51:120–126. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gluz O, Nitz UA, Christgen M, Kates RE,
Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, et al:
West German study group phase III PlanB trial: First prospective
outcome data for the 21-Gene recurrence score assay and concordance
of prognostic markers by central and local pathology assessment. J
Clin Oncol. 34:2341–2349. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Thakur SS, Li H, Chan AMY, Tudor R, Bigras
G, Morris D, Enwere EK and Yang H: The use of automated Ki67
analysis to predict Oncotype DX risk-of-recurrence categories in
early-stage breast cancer. PLoS One. 13(e0188983)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nguyen B, Cusumano PG, Deck K, Kerlin D,
Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J,
et al: Comparison of molecular subtyping with BluePrint,
MammaPrint, and TargetPrint to local clinical subtyping in breast
cancer patients. Ann Surg Oncol. 19:3257–3263. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bösl A, Spitzmüller A, Jasarevic Z, Rauch
S, Jäger S and Offner F: MammaPrint versus EndoPredict: Poor
correlation in disease recurrence risk classification of hormone
receptor positive breast cancer. PLoS One.
12(e0183458)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Trihia H, Murray S, Price K, Gelber RD,
Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch
M, Gusterson BA, et al: Ki-67 expression in breast carcinoma: Its
association with grading systems, clinical parameters, and other
prognostic factors-a surrogate marker? Cancer. 97:1321–1331.
2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Marwah N, Batra A, Marwah S, Gupta V,
Shakya S and Sen R: Correlation of proliferative index with various
clinicopathologic prognostic parameters in primary breast
carcinoma: A study from North India. J Cancer Res Ther. 14:537–542.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shokouh TZ, Ezatollah A and Barand P:
Interrelationships between Ki67, HER2/neu, p53, ER, and PR status
and their associations with tumor grade and lymph node involvement
in breast carcinoma subtypes: Retrospective-observational
analytical study. Medicine (Baltimore). 94(e1359)2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pelaez-Garcia A, Yébenes L, Berjón A,
Angulo A, Zamora P, Sánchez-Méndez JI, Espinosa E, Redondo A,
Heredia-Soto V, Mendiola M, et al: Comparison of risk
classification between EndoPredict and MammaPrint in
ER-positive/HER2-negative primary invasive breast cancer. PLoS One.
12(e0183452)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hannouf MB, Zaric GS, Blanchette P,
Brezden-Masley C, Paulden M, McCabe C, Raphael J and Brackstone M:
Cost-effectiveness analysis of multigene expression profiling
assays to guide adjuvant therapy decisions in women with invasive
early-stage breast cancer. Pharmacogenomics J. 20:27–46.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hinde S, Theriou C, May S, Matthews L,
Arbon A, Fallowfield L and Bloomfield D: The cost-effectiveness of
EndoPredict to inform adjuvant chemotherapy decisions in early
breast cancer. Health Policy and Technology. 8:75–83. 2019.
|
|
44
|
Harnan S, Tappenden P, Cooper K, Stevens
J, Bessey A, Rafia R, Ward S, Wong R, Stein RC and Brown J: Tumour
profiling tests to guide adjuvant chemotherapy decisions in early
breast cancer: A systematic review and economic analysis. Health
Technol Assess. 23:1–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen E, Tong KB and Malin JL:
Cost-effectiveness of 70-gene MammaPrint signature in node-negative
breast cancer. Am J Manag Care. 16:e333–e342. 2010.PubMed/NCBI
|
